2,5-Pyrrolidinedione, 1,1'-[Oxybis[(1-Oxo-2,1-Ethanediyl)Oxy]]Bis- (9Ci)

2,5-Pyrrolidinedione, 1,1'-[Oxybis[(1-Oxo-2,1-Ethanediyl)Oxy]]Bis- (9Ci)


    • Product Name 2,5-Pyrrolidinedione, 1,1'-[Oxybis[(1-Oxo-2,1-Ethanediyl)Oxy]]Bis- (9Ci)
    • Alias Succinic anhydride oligomer
    • Einecs 249-043-6
    • Mininmum Order 1g
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    757590

    Name 2,5-Pyrrolidinedione, 1,1'-[Ox ybis[(1 - Oxo - 2,1 - Ethanediyl)Oxy]]Bis - (9Ci)
    Molecular Formula C12H14N2O8
    Molar Mass 314.25 g/mol

    As an accredited 2,5-Pyrrolidinedione, 1,1'-[Oxybis[(1-Oxo-2,1-Ethanediyl)Oxy]]Bis- (9Ci) factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing 100g of 2,5 - Pyrrolidinedione, 1,1'-[Oxybis[(1 - Oxo - 2,1 - Ethanediyl)Oxy]]Bis - (9Ci) in sealed container.
    Shipping 2,5 - Pyrrolidinedione compound is shipped with strict adherence to chemical safety regulations. It's carefully packaged to prevent spills and damage, transported in specialized containers suitable for its chemical nature, ensuring safe transit.
    Storage Store 2,5 - Pyrrolidinedione, 1,1'-[Oxobis[(1 - Oxo - 2,1 - Ethanediyl)Oxy]]Bis - (9Ci) in a cool, dry place, away from heat sources and direct sunlight. Keep it in a well - sealed container to prevent moisture absorption and contact with air, which could potentially lead to decomposition. Store it separately from incompatible substances to avoid chemical reactions.
    Application of 2,5-Pyrrolidinedione, 1,1'-[Oxybis[(1-Oxo-2,1-Ethanediyl)Oxy]]Bis- (9Ci)
    The addition sequence is engineered to suppress premature hydrolysis of the activated ester during scale-up from bench to 50 L single-use bioreactor assemblies. The diglycolate-based bis-NHS ester is dissolved in anhydrous acetonitrile (Karl Fischer titre ≤30 ppm) and metered at 0.8 mL/min via a peristaltic pump into a jacketed vessel holding the antibody-drug intermediate at 4.0 °C ±0.5 °C under laminar nitrogen overlay. The target drug-to-antibody ratio (DAR) of 3.6 is achieved with a crosslinker stoichiometry of 2.2 molar equivalents relative to the cytotoxic payload amine, with excess quenching by 50 mM glycine after a contact time not exceeding 90 seconds. Conjugate heterogeneity is monitored in real time by hydrophobic interaction chromatography (HIC) on a TSKgel Butyl-NPR column (4.6 mm I.D. × 100 mm) with mobile phase A: 1.5 M ammonium sulfate, 50 mM potassium phosphate, pH 7.0, and B: 50 mM potassium phosphate, pH 7.0 with 20% isopropanol. Process intermediates are held to the aggregate specification of ≤ 0.5% high-molecular-weight species by SEC-MALS before tangential flow filtration with a 30 kDa regenerated cellulose membrane concentrates the conjugate to 15 mg/mL. The terminal product is an aseptically filled lyophilized cake in a 10R Type I borosilicate glass vial with a label-claim DAR range of 3.2–4.0. Pharmacopoeial compliance for residual solvents follows USP <467> Option 2, with acetonitrile capped at 410 ppm and DMSO at ≤ 5000 ppm, while impurity profiling adheres to ICH Q6B guidelines for glycoconjugate characterization. Any nitrogen-blanketed intermediate held beyond 4 hours at 2–8 °C is subjected to subvisible particle testing per USP <787> using a light obscuration counter.

    What Engineering Controls Mitigate NHS Ester Hydrolysis During Continuous-Flow Immobilisation onto Carboxylated Magnetic Beads?

    When the diglycolate crosslinker is employed to coat 2.8 µm superparamagnetic iron oxide beads with a capture antibody for chemiluminescent immunoassay kits, the aqueous solubility limitation introduces a dimensionless Damköhler number constraint that dictates the microfluidic mixing geometry. A serpentine reactor channel with hydraulic diameter 0.5 mm and an in-line static mixer element at a Reynolds number of 180 produces a residence-time distribution where 92% of the fluid elements experience a contact time of 45 ± 3 seconds before the activated bead stream encounters a 200 mM ethanolamine, pH 8.5 quenching solution. The crosslinker is pre-activated onto the bead surface via EDC/sulfo-NHS chemistry at a density of 1.2 × 10⁴ NHS groups per µm², after which the bis-NHS diglycolate is introduced at a molar ratio of 0.8:1 relative to the surface NHS esters to form a semi-permanent spacer arm that resists nucleophilic displacement during storage in 50 mM MES, 0.1% BSA, pH 6.0 at 37 °C. Real-time process analytical technology (PAT) integration employs attenuated total reflectance Fourier-transform infrared (ATR-FTIR) spectroscopy with a diamond probe immersed in the flow cell, tracking the disappearance of the asymmetric carbonyl stretch at 1812 cm⁻¹ to hold the coupling efficiency within a 5% drift band. Conjugation yield is quantified offline by a ninhydrin-based free-amine assay referenced to a glycine standard curve (linear range 0.02–0.5 µmol/mL, R² >0.995). The final reagent is a homogeneous bead suspension in 10 mM Tris, 150 mM NaCl, 0.05% ProClin 950, pH 7.6, filled into 100 mL high-density polyethylene bottles and sterilized by gamma irradiation at 25 kGy. Design control documentation is maintained under ISO 13485:2016 Clause 7.3, and the product is registered as a component of a class B in vitro diagnostic medical device under EU IVDR 2017/746 Annex VIII, category 1.2.Surgeons handling hydrated gelatin-alginate interpenetrating networks require a crosslink density gradient that can be spatially decoupled from the UV-initiated radical density to prevent the stiffening modulus from deviating beyond 30 kPa at the tissue interface. The diglycolate bis-NHS ester is dissolved in a 20% w/w Pluronic F-127 chilled aqueous coprocessed with the polysaccharide phase at 2.0 °C before being coextruded through a 1.2 mm dual-lumen static mixer tip with the gelatin phase, where the crosslinker addition rate corresponds to 0.3 mmol NHS per gram of total protein. Gelation kinetics determined by oscillatory rheometry at 1 Hz frequency, 0.1% strain amplitude indicate a sol-gel transition at 14.8 ± 0.7 °C with a storage modulus plateau of 8.3 kPa for a 1.5 mm thick film intended for post-operative adhesion prevention. The process window is narrowed by the hydrolytic half-life of the terminal NHS group in unbuffered water at 25 °C, measured at 28 minutes by stopped-flow conductometry; any deviation in the residence time of the mixed precursor beyond 6 minutes results in a 17% reduction in the elastic component of the complex modulus, as corroborated by texture analysis of the cured film after 24 hours immersion in simulated peritoneal fluid at 37 °C. The aseptic processing stage requires endotoxin reduction by tangential flow filtration through a 100 kDa polyethersulfone cassette, targeting <0.06 EU/mg device per USP <161>. The final presentation is a sterile-packed pre-filled double-syringe applicator system with a polypropylene static mixing tip, validated for shelf stability at 2–8 °C for 18 months per ASTM F1980-21 accelerated aging using Arrhenius kinetics with Q₁₀ = 2.2. Biocompatibility evaluation follows ISO 10993-1:2018 endpoints for a surface-contacting, long-term implant: cytotoxicity (ISO 10993-5, agarose overlay), intracutaneous reactivity, and ASTM F756 hemolysis index (acceptance value <2%).
    Stopped-Flow Hydrolysis Half-Life of the Bis-NHS Diglycolate Ester in Selected Aqueous Buffer Systems
    Buffer CompositionpH (at 23°C)Temperature (°C)Observed t₁⁄₂ (min)Analytical Method
    50 mM sodium phosphate, no NaCl7.40 ± 0.0223.0 ± 0.541UV decay at 260 nm (1 mm path length flow cell)
    100 mM borate, 50 mM NaCl8.20 ± 0.0323.0 ± 0.512Conductometric time-course with automated injection
    50 mM MES, 100 mM NaCl6.00 ± 0.024.0 ± 0.5185Reversed-phase HPLC; relative peak area integration
    Deionized water (unbuffered)5.78 (measured)25.0 ± 0.228Stopped-flow conductometry

    Lyophilized Protein-Micelle Crosslinking Monitored by Fluorometric Free Amine Depletion

    In the manufacture of sub-100 nm protein-loaded polymeric micelles intended for passive tumour accumulation via the enhanced permeability and retention (EPR) effect, the diglycolate crosslinker functions as a core-stabilizing agent that covalently bridges adjacent lysine residues of the encapsulated therapeutic enzyme. The micelle shell is composed of a poly(ethylene glycol)-block-poly(ε-caprolactone) diblock copolymer (Mₙ 5kDa-b-3.5kDa) that is dissolved in tetrahydrofuran and nanoprecipitated into 10 mM HEPES, pH 7.4 containing the enzyme at 2.5 mg/mL. The crosslinker, predissolved in anhydrous dimethylformamide (0.5% v/v relative to the aqueous phase), is injected into the micelle suspension at a molar NHS-to-lysine ratio of 1.5:1, with the stirring speed maintained at 400 rpm in a glass-lined reactor. After 20 minutes of coupling, the percentage of free primary amines is reduced by 63% as quantified by an ortho-phthalaldehyde (OPA) fluorometric assay using excitation wavelength 340 nm and emission 455 nm, calibrated against a lysine standard in the range 0.01–0.8 mM. Crosslinked micelles are subjected to diafiltration with 10 volumes of sucrose-containing cryoprotectant solution across a 100 kDa polyethersulfone hollow-fiber module before lyophilization in a 24 m² shelf freeze-dryer with annealing at -10 °C for 4 hours. The terminal dosage form is a sterile lyophilized powder for injection that reconstitutes in < 30 seconds with Water for Injection to yield micelles with a polydispersity index (PDI) of 0.12 by dynamic light scattering. Quality specifications include endotoxin content ≤ 0.5 EU/mg and residual THF ≤ 720 ppm per ICH Q3C (Class 2 solvent), with the manufacturing suite operating under ISO 14644-1 Class 7 background and ISO 5 unidirectional-airflow filling zones.

    When Residual Solvating DMF Interferes with the Glass Transition of PLGA Microsphere Scaffolds

    The incorporation of the diglycolate linker into poly(lactic-co-glycolic acid) (PLGA, 50:50 lactide:glycolide, inherent viscosity 0.42 dL/g) microspheres via a solid-in-oil-in-water (S/O/W) double emulsion demands strict control over the organic internal phase composition to prevent plasticization that depresses the polymer Tg below 37 °C. The crosslinker is co-dissolved with the protein-loaded trehalose microparticles and PLGA in a mixture of dichloromethane and ethyl acetate (80:20 v/v), where residual dimethylformamide from the crosslinker stock must be kept below 0.2% v/v to avoid a Tg drop exceeding 4 °C, as measured by modulated differential scanning calorimetry (MDSC) at a heating ramp of 3 °C/min with a modulation amplitude of ±0.5 °C every 60 seconds. Microsphere formation uses an in-line Silverson rotor-stator homogenizer operated at 5000 rpm followed by solvent extraction in a 2% w/v polyvinyl alcohol (13–23 kDa, 87–89% hydrolyzed) continuous phase sparged with nitrogen. The crosslinker is present at 0.8 wt% relative to PLGA mass, creating a nominal crosslink density that reduces initial burst release from 28% to 9% in a 24-hour in vitro release study using PBS with 0.02% Tween 80 at 37 °C. Terminal sterilization is performed by gamma irradiation at 15 kGy on dry ice, and the final product is a vialed microsphere powder for reconstitution with a diluent syringe, forming an extended-release suspension with a label indication for monthly administration. Compendial testing aligns with Ph. Eur. 2.9.34 for bulk density and tapped density, and residual ethylene oxide post-sterilization is verified at ≤ 1 µg/g per ISO 10993-7:2008.
    Representative Residual Solvent and Crosslinker Impurity Limits Applied to Terminal Dosage Forms Manufactured with the Bis-NHS Diglycolate Ester
    AnalyteAnalytical TechniqueAcceptance CriterionReference Standard
    N-Hydroxysuccinimide (free NHS)Ion-exclusion HPLC with UV detection at 220 nm≤ 0.15% w/w of drug substanceICH Q3A(R2); USP monograph for polysorbate impurities (analogous approach)
    Diglycolic acid (hydrolysis product)Anion-exchange chromatography with suppressed conductivity≤ 0.5 µg/mg proteinEP 5.12 Water for Injectants, conductivity-based limit transfer
    DimethylformamideHeadspace GC-FID (DB-624 column, 30 m × 0.32 mm)≤ 880 ppmICH Q3C, Class 2 residual solvent
    AcetonitrileHeadspace GC-FID≤ 410 ppmUSP <467> Procedure A
    EndotoxinKinetic chromogenic LAL assay (Endosafe® system)< 0.25 EU/mg for injectables, < 0.05 EU/device for implantablesUSP <85>, Ph. Eur. 2.6.14
    The terminal reactive group of a monomethoxy poly(ethylene glycol) amine (mPEG-NH₂, Mw 20 kDa, polydispersity 1.02) is functionalized with the diglycolate spacer to generate a PEGylated intermediate that can be conjugated to the N-terminus of a recombinant interferon alpha-2b variant expressed in Escherichia coli inclusion bodies. The reaction is conducted in a 10 mM sodium borate, pH 8.8 buffer with the PEG-amine at 12 mg/mL and the bis-NHS ester added in a single 1.0 molar equivalent shot, yielding a monoactivated PEG-diglycolate-NHS ester after 8 minutes with ≥ 94% conversion monitored by size-exclusion HPLC with an evaporative light scattering detector. Following desalting on a Sephadex G-25 Fine column equilibrated with 20 mM sodium phosphate, 50 mM NaCl, pH 6.5, the activated PEG is combined with the refolded cytokine at a 3:1 molar excess and stirred for 30 minutes at 20 °C. The conjugation mixture is resolved by cation-exchange chromatography (SP Sepharose Fast Flow, linear gradient of 0–0.5 M NaCl) to isolate the mono-PEGylated species, achieving 97% regioselectivity at the N-terminal alanine. Ultrafiltration through a 10 kDa Biomax polyethersulfone membrane concentrates the pool to 8 mg/mL, and the bulk drug substance is formulated in 10 mM sodium succinate, 150 mM sodium chloride, 0.01% polysorbate 80, pH 5.2 before 0.22 µm aseptic filtration into cyclic olefin copolymer vials. The finished product is a ready-to-use liquid injectable for subcutaneous administration, dosed weekly. Stability-indicating assays include SEC-HPLC for aggregate (≤ 2%), peptide mapping for oxidation-prone methionine residues, and cell-based anti-proliferative potency referenced to the WHO international standard for interferon alpha-2b (NIBSC code 95/566). The manufacturing control strategy is codified in a process validation master plan compliant with ICH Q11 principles, where the critical quality attribute of crosslinker-related purity is linked to the design space of PEG activation time and temperature.
    Free Quote

    Competitive 2,5-Pyrrolidinedione, 1,1'-[Oxybis[(1-Oxo-2,1-Ethanediyl)Oxy]]Bis- (9Ci) prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction
    2,5-Pyrrolidinedione, 1,1'-[oxybis[(1-oxo-2,1-ethanediyl)oxy]]bis- (9CI), cataloged under CAS 168736-87-8 and commonly referred to as bis(succinimidyl) oxydiacetate or the diglycolic acid di‑N‑hydroxysuccinimide ester, is a crystalline homobifunctional amine‑reactive crosslinker with the molecular formula C₁₂H₈N₂O₉ (calculated anhydrous molecular weight 324.2 g/mol). The bridge architecture features two activated N‑oxysuccinimidyl ester termini symmetrically connected through an oxybis(1‑oxo‑2,1‑ethanediyl) core—a central ether oxygen flanked by two carbonyl‑methylene‑ester units—yielding a spacer arm of approximately 6.5 Å (extended conformation, DFT‑optimized). This short, polar linker restricts rotational freedom and places reactive carbonyl carbons in close proximity, making the compound suitable for zero‑length analogue applications where a minimal but hydrophilic covalent tether is required. Commercial lots are typically off‑white to white microcrystalline powders stored under argon at −20 °C and must be warmed to ambient temperature inside a desiccator before opening to prevent moisture condensation.

    What Distinguishes This Oxydiacetate‑Bridged Crosslinker from Aliphatic Homologues?

    Structural differences to widely adopted homobifunctional NHS esters such as disuccinimidyl suberate (DSS, CAS 68528-80-3), bis(sulfosuccinimidyl)suberate (BS³, CAS 82436-77-9), and dithiobis(succinimidyl propionate) (DSP, CAS 57757-57-0) are summarized in the comparative matrix below. The oxydiacetate backbone introduces an ether dipole that markedly increases solubility in polar aprotic solvents and aqueous‑cosolvent mixtures while simultaneously reducing the spacer length relative to suberate‑based reagents. Consequently, crosslinking distance distributions are narrower, favoring intramolecular loop formation over intermolecular oligomerization when applied to compact proteins.
    PropertyOxydiacetate bis‑NHS ester (this product)DSSBS³DSP
    Spacer arm (Å, extended)6.511.411.412.0
    Molecular weight (g/mol)324.2368.3534.4 (sodium salt)404.4
    Backbone charge at pH 7.0NeutralNeutralDianionic (sulfonate)Neutral
    CleavableNo (stable ether)NoNoYes (disulfide, reductant‑labile)
    Solubility in water at 25 °C (mM)<0.2 (neat); >10 with 5% DMF<0.1>50<0.1
    The absence of a cleavable site means the ether‑containing adduct withstands reducing conditions (e.g., 50 mM DTT, 37 °C, 24 h) but remains susceptible to strong alkaline hydrolysis of the N‑succinimidyl carbamate‑analogous ester linkages. This property is exploited in forced‑degradation studies where peptide‑crosslinker conjugates are incubated in 0.1 M NaOH at 50 °C for complete ester scission.

    Solubility and Hydrolytic Stability in Aqueous Reaction Milieu

    Freshly desiccated compound dissolves readily in anhydrous dimethylformamide (DMF) or dimethyl sulfoxide (DMSO) up to a concentration of 250 mg/mL; stock solutions should be prepared immediately before use and discarded after 4 h if stored at room temperature. Upon injection into a stirred, de‑gassed phosphate buffer (50 mM, pH 7.4, 25 °C) containing up to 5% (v/v) DMSO as co‑solvent, pseudo‑first‑order hydrolysis of the active ester proceeds with an observed half‑life of 17 ± 3 min, as determined by monitoring the release of N‑hydroxysuccinimide via HPLC with 260 nm detection (C18 column, isocratic elution 95:5 H₂O/MeCN + 0.1% TFA). This kinetic profile is comparable to that of suberate‑based esters under identical conditions but shifts sharply when pH exceeds 8.0: the half‑life falls below 3 min at pH 8.5 because the ether oxygen’s inductive effect slightly accelerates hydroxide attack at the carbonyl. Practical conjugation protocols therefore mandate a pH window of 6.8–7.5 and a reaction quench with Tris (final concentration 50 mM) after 30–60 min to scavenge unreacted ester. The short tether yields a low probability of crosslinker self‑oligomerization when the target biomolecule’s surface lysine density exceeds 3 µmol/m². Under these conditions, the dominant path is monofunctional amine acylation with unreacted second ester pendent, which can later undergo slow hydrolysis or be captured by a second amine partner if the conjugate is not desalted. Size‑exclusion chromatography (SEC) on a Superdex 75 Increase column frequently resolves peaks corresponding to singly modified, doubly crosslinked, and aggregated species; the ratio of desired crosslinked product to singly modified intermediate is monitored by integrating the 280 nm absorbance and corroborating with TNBS assay (performed per Habeeb, Anal. Biochem. 14, 328, 1966). For reactions where nonspecific surface grafting onto amine‑terminated self‑assembled monolayers (SAMs) or amino‑functionalized magnetite nanoparticles (average diameter 50 nm) is performed, an initial coupling incubation of 2 h at 4 °C under gentle vortexing, followed by a 30 min block with ethanolamine (pH 8.0), produces a uniform amide‑linked adlayer. X‑ray photoelectron spectroscopy (XPS) survey scans of the resulting surfaces show a nitrogen‑to‑carbon (N1s/C1s) ratio increase of 0.12 ± 0.02 relative to unmodified controls, consistent with a monolayer coverage of approximately 3.8 molecules/nm² when referenced to a succinimidyl ester footprint model. The ether‑containing bridge imparts an elution volume shift on reverse‑phase HPLC relative to purely aliphatic crosslinkers; under a standard water/acetonitrile gradient (5→95% over 25 min), the intact diester elutes at 14.2 min while the singly hydrolyzed mono‑ester appears at 12.7 min. This resolution enables the use of HPLC‑MS to confirm batch purity and quantitate hydrolytic degradation products that accumulate when storage protocols are breached.

    When High Moisture Exposure Compromises Crosslinking Efficiency

    Production‑scale observations highlight that repeated opening of the storage container under ambient humidity (> 60% RH) leads to a measurable drop in active ester content within 48 h. In a controlled stability trial, aliquots exposed to 75% RH at 25 °C for 72 h showed a reduction in coupling efficiency toward hen egg‑white lysozyme (HEWL, 14.3 kDa) from 85 ± 3% to 41 ± 5%, as quantified by MALDI‑TOF mass shift. The failure mode is hydrolysis of one arm of the diester, generating an unreactive carboxylic acid and liberating N‑hydroxysuccinimide, which can further catalyze autocatalytic degradation at elevated temperatures. Pre‑drying of the powder over phosphorus pentoxide (24 h, 0.1 mbar) can partially reverse the loss, but recovery beyond 70% of initial activity is uncommon; therefore the product is supplied in single‑use septum‑capped vials under argon overlay. On a preparative scale (>100 mg), dissolution should be performed in an anhydrous glovebox and aliquots dispensed via a positive‑displacement pipette into dry reaction vessels to avoid water uptake.
    ParameterSpecificationAnalytical Method
    AppearanceWhite to off‑white crystalline powderVisual, against #FFFFFF reference
    Assay (HPLC, anhydrous basis)98.0%HPLC, C18, 254 nm, area normalization
    Moisture content0.5% (w/w)Karl Fischer coulometric titration
    Free N‑hydroxysuccinimide1.0%HPLC, 260 nm, external standard
    Solubility in DMF (clear solution)Pass at 200 mg/mLDissolution in anhydrous DMF, visual inspection
    Melting / decomposition range118–124 °C (dec.)DSC, 10 °C/min under N₂
    The dual‑ester architecture imposes a stoichiometric constraint: a 2‑fold molar excess of crosslinker over target amine groups is typically sufficient for maximal coupling when amine concentration is kept below 0.5 mg/mL, whereas a 5‑fold excess is required if amine‑to‑amine spacing is sterically hindered, as in the case of human hemoglobin where the β‑chain N‑terminus and lysine‑82 are partially occluded by the quaternary T‑state interface. Exceeding a 10‑fold excess promotes inter‑protein dimerization even at dilute protein concentrations (0.1 mg/mL), and dynamic light scattering (DLS) reports a shift from a hydrodynamic radius of 3.1 nm (monomer) to 6.8 nm (covalent dimer) within 15 min of addition. The relatively low molecular weight and absence of ionizable backbone groups exclude this crosslinker from applications that require a charged spacer or an extended, flexible scaffold. When a longer spacer with enhanced aqueous solubility is essential, the sulfonated suberate analog BS³ is the standard replacement, albeit at the cost of a different crosslink‑site geometry that may not replicate the constrained juxtamembrane crosslinking achieved with the oxydiacetate linker. In proteomics sample preparation where disulfide‑cleavable crosslinks are needed for MS‑cleavable ion signature detection, DSP or its sulfonated variants are chosen over the non‑cleavable ether bridge of this compound. Dissolved conjugates retaining one unreacted ester arm can be stored in buffered glycerol (50% v/v) at −80 °C for up to 72 h without significant further intermolecular reaction, enabling staged, sequential conjugation workflows. However, lyophilization of monofunctional intermediates is not recommended because eutectic salt concentration during freezing accelerates ester hydrolysis, yielding up to 15% dead‑arm termini within a single freeze‑thaw cycle as measured by subsequent amine‑capture titration with fluorescein cadaverine.